Literature DB >> 21195803

Long term recall of memory CD8 T cells in mice to first and third generation smallpox vaccines.

Sharone Green1, Francis A Ennis, Anuja Mathew.   

Abstract

Since long-term immunity is a critical component of any effective vaccine, we compared over a 15-month period, the strength, durability and specificity of immunity of an attenuated smallpox vaccine Modified Vaccinia Ankara (MVA) to the New York City Board of Health (NYCBH) vaccine. The frequencies of CD8(+) T cells to an immunodominant CD8 T cell epitope B8R(20-27) remained remarkably stable in mice given either MVA or NYCBH. Both groups were also protected from a lethal intranasal challenge with Western Reserve strain of vaccinia virus (VACV-WR). Cytokine responses to virus-specific peptides were detectable with significant boosting upon challenge. Expression of most phenotypic markers that define antigen-specific memory CD8 T cells was similar while CD27 was differentially expressed on lung-specific T cells compared to the spleen. Our data indicate robust vaccinia-specific CD8(+) T cell recall responses to lethal secondary challenge in protected mice with no apparent effect of age on T cell pools established much earlier in life.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21195803      PMCID: PMC3034797          DOI: 10.1016/j.vaccine.2010.12.036

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  46 in total

1.  Duration of antiviral immunity after smallpox vaccination.

Authors:  Erika Hammarlund; Matthew W Lewis; Scott G Hansen; Lisa I Strelow; Jay A Nelson; Gary J Sexton; Jon M Hanifin; Mark K Slifka
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

2.  Modified vaccinia Ankara: potential as an alternative smallpox vaccine.

Authors:  Lewis H McCurdy; Brenda D Larkin; Julie E Martin; Barney S Graham
Journal:  Clin Infect Dis       Date:  2004-05-19       Impact factor: 9.079

3.  Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.

Authors:  H Meyer; G Sutter; A Mayr
Journal:  J Gen Virol       Date:  1991-05       Impact factor: 3.891

Review 4.  T-cell memory and recall responses to respiratory virus infections.

Authors:  Hirokazu Hikono; Jacob E Kohlmeier; Kenneth H Ely; Iain Scott; Alan D Roberts; Marcia A Blackman; David L Woodland
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

5.  Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8, and their Lister original (LO) strains.

Authors:  M Sugimoto; A Yasuda; K Miki; M Morita; K Suzuki; N Uchida; S Hashizume
Journal:  Microbiol Immunol       Date:  1985       Impact factor: 1.955

6.  [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].

Authors:  H Stickl; V Hochstein-Mintzel; A Mayr; H C Huber; H Schäfer; A Holzner
Journal:  Dtsch Med Wochenschr       Date:  1974-11-22       Impact factor: 0.628

7.  [Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures].

Authors:  A Mayr; E Munz
Journal:  Zentralbl Bakteriol Orig       Date:  1964-12

8.  NYVAC: a highly attenuated strain of vaccinia virus.

Authors:  J Tartaglia; M E Perkus; J Taylor; E K Norton; J C Audonnet; W I Cox; S W Davis; J van der Hoeven; B Meignier; M Riviere
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

9.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

10.  Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.

Authors:  James T Snyder; Igor M Belyakov; Amiran Dzutsev; François Lemonnier; Jay A Berzofsky
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more
  1 in total

1.  Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.

Authors:  Berislav Bošnjak; Ivan Odak; Joana Barros-Martins; Inga Sandrock; Swantje I Hammerschmidt; Marc Permanyer; Gwendolyn E Patzer; Hristo Greorgiev; Rodrigo Gutierrez Jauregui; Alina Tscherne; Jan Hendrik Schwarz; Georgia Kalodimou; George Ssebyatika; Malgorzata Ciurkiewicz; Stefanie Willenzon; Anja Bubke; Jasmin Ristenpart; Christiane Ritter; Tamara Tuchel; Christian Meyer Zu Natrup; Dai-Lun Shin; Sabrina Clever; Leonard Limpinsel; Wolfgang Baumgärtner; Thomas Krey; Asisa Volz; Gerd Sutter; Reinhold Förster
Journal:  Front Immunol       Date:  2021-11-11       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.